A surgical strategy for lower grade gliomas using intraoperative molecular diagnosis

[1]  T. Maruyama,et al.  Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. , 2018, World neurosurgery.

[2]  H. Iseki,et al.  Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. , 2017, Journal of neurosurgery.

[3]  A. Jarmusch,et al.  Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry , 2017, Proceedings of the National Academy of Sciences.

[4]  Hiromichi Suzuki,et al.  A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma , 2017, Brain Tumor Pathology.

[5]  E. Maher,et al.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Satoshi O. Suzuki,et al.  Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data , 2016, PloS one.

[7]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[8]  A. Mukasa,et al.  Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. , 2016, Neuro-oncology.

[9]  M. Tamura,et al.  Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas , 2016, Brain Tumor Pathology.

[10]  Hiromichi Suzuki,et al.  Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe , 2016, Cancer investigation.

[11]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[12]  K. Ichimura,et al.  Revisiting TP53 Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas , 2015, Brain pathology.

[13]  Satoru Miyano,et al.  Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.

[14]  S. Lam,et al.  Predictors of survival in patients with spinal ependymoma , 2015, Neurological research.

[15]  Hiroshi Iseki,et al.  Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. , 2015, Neurosurgical focus.

[16]  T. Tominaga,et al.  Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma. , 2014, Journal of neurosurgery.

[17]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.

[18]  M. J. van den Bent,et al.  New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. , 2013, European journal of cancer.

[19]  T. Holland-Letz,et al.  ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis , 2013, Acta Neuropathologica.

[20]  H. Iseki,et al.  Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. , 2013, Neurologia medico-chirurgica.

[21]  Hiroshi Iseki,et al.  Intraoperative flow cytometry analysis of glioma tissue for rapid determination of tumor presence and its histopathological grade: clinical article. , 2013, Journal of neurosurgery.

[22]  H. Duffau.  A new philosophy in surgery for diffuse low-grade glioma (DLGG): oncological and functional outcomes. , 2013, Neuro-Chirurgie.

[23]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Nader Sanai,et al.  The Value of Glioma Extent of Resection in the Modern Neurosurgical Era , 2012, Front. Neur..

[26]  Andrey Korshunov,et al.  Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations , 2012, Acta Neuropathologica.

[27]  I. Yang,et al.  Awake surgery for WHO grade II gliomas within “noneloquent” areas in the left dominant hemisphere: toward a “supratotal” resection , 2012 .

[28]  Hugues Duffau,et al.  Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. , 2011, Journal of neurosurgery.

[29]  A. Heimberger,et al.  AWAKE CRANIOTOMY FOR BRAIN TUMORS NEAR ELOQUENT CORTEX: CORRELATION OF INTRAOPERATIVE CORTICAL MAPPING WITH NEUROLOGICAL OUTCOMES IN 309 CONSECUTIVE PATIENTS , 2009, Neurosurgery.

[30]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.